Management of metastatic colorectal cancer (mCRC) of the liver presents a complex challenge to oncologists and multidisciplinary treatment teams.

Selective internal radiation therapy (SIRT) with SIR-Spheres® Y-90 resin microspheres administered by interventional radiologists is an approved local therapy for the management of mCRC liver tumors.

  • Approximately 100,000 doses have been administered in more than 1300 treatment centres worldwide.
  • New data from an array of large, multi-centre, international studies support expanded use of SIR-Spheres Y-90 resin microspheres in appropriate patients.

In First Line Treatment of mCRC:

  • A post hoc analysis from two RCTs, SIRFLOX and FOXFIRE Global, indicates that the addition of SIR-Spheres Y-90 resin microspheres to chemotherapy in patients with the primary tumour originating from the right-side of the colon, significantly increases the overall survival (OS). These data were presented at European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (WCGIC), 2017.
  • A retrospective analysis (REsect) of data from the first-line SIRFLOX study demonstrated a significant increase in potential resection of liver metastases when SIR-Spheres Y-90 resin microspheres were added to chemotherapy. The data from the REsect study were presented at the 12th International Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), May 2017.
  • Clinical studies in refractory mCRC have shown that SIR-Spheres Y-90 resin microspheres increase the time to progression and prolong overall survival.1-3 In first-line treatment in mCRC, adding SIR-Spheres Y-90 resin microspheres to FOLFOX-based chemotherapy did not diminish patients' quality of life.4,5

Beyond First Line Treatment in mCRC:

  • Radioembolisation with SIR-Spheres Y-90 resin microspheres has demonstrated a clinically significant benefit in overall survival in multiple clinical studies, leading to the recommendation of SIRT with SIR-Spheres Y-90 resin microspheres by the ESMO and the NCCN clinical practice guidelines for colon cancer.

1. Hendlisz et al. J Clin Oncol 2010; 28: 3687–94.
2. Seidensticker et al. Cardiovasc Interv Radiol 2012; 35; 1066‒73.
3. Bester et al. J Vasc Interv Radiol 2012; 23: 96–105.
4. Van Hazel G et al. J Clin Oncol 2016; 34: 1723–1731.
5. Wasan HS et al. Lancet Oncology 2017 Aug 3; ePub doi: 10.1016/S1470-2045(17)30457-6

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.